Skip to main content
. Author manuscript; available in PMC: 2022 Jan 4.
Published in final edited form as: Int J Cancer. 2013 Apr 11;133(7):1643–1652. doi: 10.1002/ijc.28163

Figure 1. Increased NK cell-mediated killing of doxorubicin-treated allogeneic and autologous tumor cells.

Figure 1

(A) J82 tumors (allogeneic) and GEWA-MEL tumors (autologous) were treated with 200 ng/ml doxorubicin and tested for susceptibility to NK cell-mediated killing in an 18h 51Cr-release assay. (B) Summary of 51Cr-release assays of allogeneic (n=6, p<0.01) and autologous (n=4, p< 0.05) NK cell killing of J82 and GEWA-MEL cell lines respectively. Effector-target (E:T) ratios ranged from 0.1:1–3:1, UNT = untreated, DOX = doxorubicin-treated.